Antiparkinson Agents

"Antiparkinson Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Descriptor ID	D000978
MeSH Number(s)	D27.505.954.427.090.050
Concept/Terms	Antiparkinson Agents Antiparkinson Agents Agents, Antiparkinson Antiparkinsonian Agents Agents, Antiparkinsonian Antiparkinsonians Antiparkinson Drugs Drugs, Antiparkinson

Below are MeSH descriptors whose meaning is more general than "Antiparkinson Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Anti-Dyskinesia Agents [D27.505.954.427.090]
Antiparkinson Agents [D27.505.954.427.090.050]

Below are MeSH descriptors whose meaning is related to "Antiparkinson Agents".

Below are MeSH descriptors whose meaning is more specific than "Antiparkinson Agents".

Antiparkinson Agents
Aromatic Amino Acid Decarboxylase Inhibitors
Catechol O-Methyltransferase Inhibitors

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antiparkinson Agents" by people in this website by year, and whether "Antiparkinson Agents" was a major or minor topic of these publications.

Bar chart showing 3 publications over 3 distinct years, with a maximum of 1 publications in 2010 and 2020 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	0	1	1
2020	0	1	1
2021	1	0	1

Below are the most recent publications written about "Antiparkinson Agents" by people in Profiles.

Singh S, Cocoros NM, Haynes K, Nair VP, Harkins TP, Rochon PA, Platt R, Dashevsky I, Reynolds J, Mazor KM, Bloomstone S, Anzuoni K, Crawford SL, Gurwitz JH. Antidopaminergic-Antiparkinsonian Medication Prescribing Cascade in Persons with Alzheimer's Disease. J Am Geriatr Soc. 2021 05; 69(5):1328-1333.

View in: PubMed
Szlufik S, Duszynska-Lysak K, Przybyszewski A, Laskowska-Levy I, Drzewinska A, Dutkiewicz J, Mandat T, Habela P, Koziorowski D. The potential neuromodulatory impact of subthalamic nucleus deep brain stimulation on Parkinson's disease progression. J Clin Neurosci. 2020 Mar; 73:150-154.

View in: PubMed
Ramirez-Zamora A, Gee L, Youn Y, Shin DS, Pilitsis JG. Pallidal Deep Brain Stimulation for the Treatment of Levodopa-Responsive Juvenile Dystonia and Parkinsonism Secondary to SPG11 Mutation. JAMA Neurol. 2017 01 01; 74(1):127-128.

View in: PubMed
Kaszuba BC, Walling I, Gee LE, Shin DS, Pilitsis JG. Effects of subthalamic deep brain stimulation with duloxetine on mechanical and thermal thresholds in 6OHDA lesioned rats. Brain Res. 2017 01 15; 1655:233-241.

View in: PubMed
Gee L, Smith H, De La Cruz P, Campbell J, Fama C, Haller J, Ramirez-Zamora A, Durphy J, Hanspal E, Molho E, Barba A, Shin D, Pilitsis JG. The Influence of Bilateral Subthalamic Nucleus Deep Brain Stimulation on Impulsivity and Prepulse Inhibition in Parkinson's Disease Patients. Stereotact Funct Neurosurg. 2015; 93(4):265-70.

View in: PubMed
Rajan S, Deogaonkar M, Kaw R, Nada EM, Hernandez AV, Ebrahim Z, Avitsian R. Factors predicting incremental administration of antihypertensive boluses during deep brain stimulator placement for Parkinson's disease. J Clin Neurosci. 2014 Oct; 21(10):1790-5.

View in: PubMed
Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs Aging. 2010 Jun 01; 27(6):435-49.

View in: PubMed
May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007 Dec; 22(16):2371-7.

View in: PubMed
Tour? JT, Brandt NJ, Limcangco MR, Briesacher BA. Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted-living facilities. Am J Geriatr Pharmacother. 2006 Mar; 4(1):25-35.

View in: PubMed
Kikuchi A, Takeda A, Fujihara K, Kimpara T, Shiga Y, Tanji H, Nagai M, Ichinose H, Urano F, Okamura N, Arai H, Itoyama Y. Arg(184)His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism: a case report. Mov Disord. 2004 May; 19(5):590-3.

View in: PubMed

People

Explore

Similar Concepts

Top Journals